A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.

开始日期2020-04-30

申办/合作机构

The General Hospital Corp.

[+1]

PER-069-15

/ Recruiting临床3期

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG- TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

开始日期2016-04-01

申办/合作机构-

NCT02709486

/ Completed临床3期

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

Tanezumab is a monoclonal antibody that binds to and inhibits the actions of nerve growth factor (NGF). The Nerve Growth Factor Inhibitor (NGFI) class may offer an important breakthrough in the treatment of chronic pain and is under clinical investigation for the treatment of pain associated with osteoarthritis or other chronic pain conditions.
The primary objective of this study is to demonstrate superior efficacy of tanezumab 5 mg and 2.5 mg administered subcutaneously (SC) every 8 weeks versus placebo at Week 24 in subjects with osteoarthritis of the knee or hip. The 2.5 mg dose was shown to provide efficacy benefits with a favorable safety profile when administered intravenously in previous Phase 3 clinical trials. The 5 mg dose is expected to provide added efficacy benefit over the 2.5 mg dose based on data from previous studies.

开始日期2016-03-02

申办/合作机构

Pfizer Inc.

[+1]

100 项与 Tanezumab 相关的临床结果

登录后查看更多信息

100 项与 Tanezumab 相关的转化医学

登录后查看更多信息

100 项与 Tanezumab 相关的专利（医药）

登录后查看更多信息

150

项与 Tanezumab 相关的文献（医药）

2024-08-01·VETERINARY JOURNAL

Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs

Letter

作者: Reece, Douglas ; Cole, Phaedra ; Simon, Tony ; Werts, Adam

In their letter to the editor, Farrell et al., (2024) presented questions related to canine joint health after treatment with the anti-Nerve Growth Factor (NGF) monoclonal antibody (mAb) bedinvetmab, which was presented as a component of a non-clinical laboratory safety assessment published in Krautmann et al., (2021). Their questions appear to have stemmed from an anti-NGF mAb developed for the treatment of osteoarthritis in humans (tanezumab; FDA, 2021) which in 2021 failed to achieve marketing approval due to an unfavorable benefit: risk profile, primarily due to a syndrome called Rapidly Progressive Osteoarthritis (RPOA) which occurred more commonly in treatment groups when compared to controls. Farrell et. al. (2024) have posed questions on radiographic and histopathologic bone findings from studies included in Krautmann, et al., (2021) and communicated in the FDA's Freedom of Information summary for Librela (FDA, 2023). These findings have previously been determined to be incidental and not bedinvetmab-associated. To address the questions posed, it is important to briefly define RPOA and summarize the syndrome in humans, review why the bone/joint findings in bedinvetmab safety studies in dogs are not indicative of RPOA or an RPOA-like condition, provide an update on joint health after use of bedinvetmab since market approval (>3 years in some markets), and summarize why Zoetis, the manufacturer of Librela, has confidence in joint safety after use of bedinvetmab in dogs.

2023-12-11·The oncologist

A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis

Article

作者: Fallon, Marie ; Bao, Weihang ; Viktrup, Lars ; Agyemang, Alex ; Brown, Mark T ; Sopata, Maciej ; West, Christine R ; Dragon, Erika

Abstract:

Background:

This phase III, randomized, double-blind, placebo-controlled, parallel-group study assessed the efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy.

Methods:

Subjects were randomized (stratified by (1) tumor aggressiveness and (2) presence/absence of concomitant anticancer treatment) to placebo or tanezumab 20 mg. Treatment was administered by subcutaneous injection every 8 weeks for 24 weeks (3 doses) followed by a 24-week safety follow-up period. The primary outcome was change in daily average pain in the index bone metastasis cancer pain site (from 0 = no pain to 10 = worst possible pain) from baseline to week 8.

Results:

LS mean (SE) change in pain at week 8 was −1.25 (0.35) for placebo (n = 73) and –2.03 (0.35) for tanezumab 20 mg (n = 72). LS mean (SE) [95% CI] difference from placebo was –0.78 (0.37) [–1.52, –0.04]; P = .0381 with α = 0.0478. The number of subjects with a treatment-emergent adverse event during the treatment period was 50 (68.5%) for placebo and 53 (73.6%) for tanezumab 20 mg. The number of subjects with a prespecified joint safety event was 0 for placebo and 2 (2.8%) for tanezumab 20 mg (pathologic fracture; n = 2).

Conclusion:

Tanezumab 20 mg met the primary efficacy endpoint at week 8. Conclusions on longer-term efficacy are limited since the study was not designed to evaluate the durability of the effect beyond 8 weeks. Safety findings were consistent with adverse events expected in subjects with cancer pain due to bone metastasis and the known safety profile of tanezumab. Clinicaltrials.gov identifier: NCT02609828.

2023-12-01·Osteoarthritis and cartilage

Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab

Article

作者: Conaghan, Philip G ; Schnitzer, Tom J ; Hochberg, Marc C ; Fountaine, Robert J ; Guermazi, Ali ; Verburg, Kenneth M ; West, Christine R ; Carrino, John A ; Burr, Aimee ; Viktrup, Lars ; Pixton, Glenn C ; McAlindon, Timothy E ; Brown, Mark T

OBJECTIVE:

Due to the risk of rapidly progressive osteoarthritis (RPOA), the phase III studies of subcutaneous (SC) tanezumab in patients with moderate to severe hip or knee osteoarthritis (OA) included comprehensive joint safety surveillance. This pooled analysis summarizes these findings.

METHOD:

Joint safety events in the phase III studies of SC tanezumab (2 placebo- and 1- nonsteroidal anti-inflammatory drug [NSAID]-controlled) were adjudicated by a blinded external committee. Outcomes of RPOA1 and RPOA2, primary osteonecrosis, subchondral insufficiency fracture, and pathological fracture comprised the composite joint safety endpoint (CJSE). Potential patient- and joint-level risk factors for CJSE, RPOA, and total joint replacement (TJR) were explored.

RESULTS:

Overall, 145/4541 patients (3.2%) had an adjudicated CJSE (0% placebo; 3.2% tanezumab 2.5 mg; 6.2% tanezumab 5 mg; 1.5% NSAID). There was a dose-dependent risk of adjudicated CJSE, RPOA1, and TJR with tanezumab vs NSAID. Patient-level cross-tabulation found associations between adjudicated RPOA with more severe radiographic/symptomatic (joint pain, swelling, and physical limitation) OA. Risk of adjudicated RPOA1 was highest in patients with Kellgren-Lawrence (KL) grade 2 or 3 OA at baseline. Risk of adjudicated RPOA2 or TJR was highest in patients with KL grade 4 joints at baseline. A higher proportion of joints with adjudicated RPOA2 had a TJR (14/26) than those with adjudicated RPOA1 (16/106).

CONCLUSION:

In placebo- and NSAID controlled studies of SC tanezumab for OA, adjudicated CJSE, RPOA, and TJR most commonly occurred in patients treated with tanezumab and with more severe radiographic or symptomatic OA. NCT02697773; NCT02709486; NCT02528188.

项与 Tanezumab 相关的新闻（医药）

23 小时之前

·CPHI制药在线

礼来研发线“断舍离”：FIC药物折戟与战略棋局

关注并星标CPHI制药在线 *展会预登记火热进行中，👆扫描二维码免费领票！当医药巨头礼来在8月7日交出一份亮眼的Q2财报时，同步曝光的4个临床项目终止消息更值得玩味。从银屑病到脂肪肝，从镇痛药到免疫疗法，这些曾被寄予厚望的"潜在首创新药"（FIC）接连折戟，涉及交易总金额超亿美元。在创新药研发九死一生的定律下，礼来此举绝非简单止损，而是管线战略的主动重构。一、银屑病药物：靶点困境与招募难题 Kv1.3 是一种电压门控钾离子通道，在效应记忆 T（TEM）细胞中高度表达。在银屑病发病机制里，TEM 细胞异常激活并释放炎症因子，引发皮肤炎症与角质形成细胞过度增殖。理论上，通过抑制 Kv1.3，能够阻断 TEM 细胞的激活与增殖，从而达到治疗银屑病的目的。礼来的 LY3972406 便是基于这一机制开发的 Kv1.3 拮抗剂，2022 年礼来支付 6000 万美元首付款从 D. E. Shaw Research 公司获得该候选药物，对其寄予厚望，期望能在银屑病治疗领域开辟新路径。 2023年，礼来启动 LY3972406 治疗斑块状银屑病的 II 期试验（NCT06176768），计划招募 75 名患者，然而到 2025 年 5 月试验完成时，实际仅招募到 33 人，只有原计划的 1/3 左右。患者招募不足使得试验数据的可靠性与说服力大打折扣，也成为项目推进的巨大阻碍。回顾同类靶点研发历程，阿斯利康曾研发过基于海葵毒素 ShK 的 Kv1.3 抑制剂 ShK - 186，在临床前研究中，ShK - 186 展现出对Kv1.3 的高亲和力和选择性，在动物模型里也对自身免疫疾病，如多发性硬化症、红斑狼疮、牛皮癣、类风湿关节炎、1 型糖尿病和炎症性肠病等，有一定治疗效果。但在后续研发中，阿斯利康却放弃了该项目。主要原因在于，靶向离子通道药物面临着血脑屏障穿透难题。血脑屏障由脑微血管内皮细胞、基底膜、周细胞和星形胶质细胞等构成，是维持大脑内环境稳定的重要结构，它能阻挡有害物质进入大脑，却也限制了许多药物进入中枢神经系统。Kv1.3 不仅在 TEM 细胞表达，在中枢神经系统的神经元等细胞中也有表达。当药物抑制外周 TEM 细胞的 Kv1.3 时，如果药物穿透血脑屏障，就可能对中枢神经系统的正常生理功能产生影响，带来不可预测的副作用。LY3972406 或许也面临类似问题，尽管目前没有明确数据表明其在血脑屏障穿透方面存在问题，但从同类靶点研发困境可推测，这很可能是导致其研发失败的潜在因素之一。从 2022 年重金押注到如今折戟 II 期，LY3972406 的失败深刻体现了从基础研究到临床转化的巨大挑战。二、镇痛药：非阿片类的希望与破灭疼痛作为一种常见且困扰患者的症状，长期以来依赖麻醉镇痛药、阿片类药物、非甾体抗炎药等治疗，但这些药物存在耐受性低、毒副反应大、长期安全性差、潜在药物滥用等问题，患者急需更安全有效的镇痛药物。生长抑素受体亚型 4（SSTR4）在中枢神经系统中高度表达并介导镇痛和抗炎作用，靶向 SSTR4 的激动剂有望应用于非阿片类药物疼痛控制。2019 年，礼来以 4750 万美元首付款从 Centrexion 公司引进 mazisotine，期望它能成为解决疼痛治疗困境的 “钥匙”，作为非阿片类止痛候选药物，mazisotine 承载着礼来在疼痛治疗领域开辟新路径的厚望。今年 6 月，mazisotine 针对糖尿病周围神经病变疼痛患者的 II 期研究（NCT06074562）完成，但从既往疗效数据来看，结果 “不尽如人意” 。在骨关节炎疼痛、下腰痛等疼痛治疗试验里，mazisotine 表现不佳。以糖尿病周围神经痛治疗试验为例，8 周时mazisotine 组数值评定量表（NRS）评分降低值与安慰剂组相比，优势并不明显。在当前镇痛领域，神经生长因子（NGF）抑制剂是主流研发靶点之一。NGF 在外周痛觉过敏和炎症中发挥关键作用，参与慢性疼痛调节。抗 NGF 抗体通过阻断 NGF 与其受体结合来干扰神经系统，发挥镇痛作用。虽然辉瑞 / 礼来合作开发的 Tanezumab 因安全性问题上市之路受阻，再生元的 Fasinumab 也因安全性问题被 FDA 叫停临床试验，但众多药企仍在积极研发针对 NGF 的抗体药物，如国内达石药业的 DS002、未名生物的 SMR7694 等已获得 NMPA 临床批件。与 NGF 抑制剂相比，SSTR4 激动剂研发面临着独特困境。SSTR4 属于生长抑素受体家族，该家族有 5 个亚型。SSTR4 激动剂在研发中难以实现高度的受体亚型选择性，这导致药物在作用于 SSTR4 时，可能同时影响其他受体亚型，引发一系列副作用。比如，可能对生长激素、胰岛素等激素的分泌调节产生干扰，影响人体正常代谢功能，这成为 SSTR4 激动剂研发失败的关键因素。在 SSTR4 激动剂研发赛道，仅有mazisotine 进入 II 期临床阶段，如今礼来终止研发，使得该靶点的研发前景变得更加黯淡。三、脂肪肝疗法：siRNA 的代谢病迷障 LY3885125 是礼来研发的一款靶向 SCAP 蛋白的 siRNA 候选药物。SCAP 是一种内质网胆固醇感应膜蛋白，在细胞胆固醇以及脂质稳态调节中发挥关键作用。当细胞缺乏胆固醇时，SCAP 护送固醇调节元件结合蛋白（SREBPs）从内质网到高尔基体。随后，SREBPs 被高尔基蛋白酶裂解，其 N 端区域进入细胞核并激活靶基因转录，这些靶基因与胆固醇、脂肪酸、甘油三酯和磷脂的吸收与合成相关。在代谢功能障碍相关脂肪肝病（MASLD）发病机制里，过量脂肪酸引发肝脏脂肪变性和胰岛素抵抗，而SCAP/SREBP 正是脂肪酸合成的关键途径。LY3885125 的设计思路是通过 RNA 干扰机制，特异性地沉默 SCAP 蛋白的 mRNA 表达，从而阻断 SCAP 对 SREBPs 的护送，抑制脂肪酸等脂质合成相关基因转录，减少肝脏脂质沉积，达到治疗 MASLD 的目的。这一设计在理论上具有创新性与可行性，为 MASLD 治疗提供了新方向。 MASLD 具有高度异质性。从发病机制来看，虽然都涉及肝脏脂肪代谢异常，但不同患者的病因可能不同，包括遗传因素（如某些基因突变影响脂质代谢酶活性）、环境因素（如高热量饮食、缺乏运动、暴露于内分泌干扰物等）、肠道菌群失衡（有益菌减少、有害菌增加、菌群代谢产物改变影响肝脏代谢）以及代谢综合征相关因素（肥胖、高血压、2 型糖尿病等常与 MASLD 并存并相互影响）。从疾病进展与临床表现来看，不同患者的肝脏脂肪变性程度、炎症活动程度、纤维化进程差异很大。有的患者可能仅表现为单纯性脂肪肝，病情进展缓慢；而有的患者可能迅速发展为脂肪性肝炎、肝纤维化甚至肝硬化。这种异质性使得 LY3885125 的疗效验证困难重重。不同病因、不同疾病阶段的患者对药物反应可能不同。比如，对于因遗传因素导致脂质代谢关键酶缺乏的患者，单纯抑制 SCAP 可能无法有效改善肝脏脂质代谢；对于肠道菌群严重失衡的患者，肠道来源的内毒素等有害物质持续进入肝脏，干扰肝脏正常代谢，即使 SCAP 被抑制，肝脏病变仍可能难以缓解。礼来在 2 月份终止 LY3885125 的一项研究后，曾计划优化患者人群并启动新试验，但最终还是失败。这是因为 MASLD 的疾病分型复杂性远超预期。目前缺乏精准有效的生物标志物来准确划分患者亚型，难以筛选出对 LY3885125 可能有良好反应的患者群体。即便通过一些临床指标（如肝功能指标、血脂指标等）和影像学检查（如肝脏超声、MRI 等）进行初步筛选，也无法全面准确反映患者肝脏代谢的内在特征与疾病本质。这一失败案例充分折射出代谢病领域精准分层的迫切性。只有实现精准分层，明确不同亚型患者的发病机制、病理生理特征以及对药物的反应差异，才能开发出更具针对性、更有效的治疗药物。四、衣康酸败局：免疫调控的风险警示 LY3839840 是礼来在 2020 年与 Sitryx 公司签署协议时获得的衣康酸模拟物。在自身免疫和炎症性疾病治疗领域，衣康酸及其相关通路成为研究热点。衣康酸是巨噬细胞等免疫细胞在炎症刺激下，由顺乌头酸脱羧酶 1（ACOD1）催化顺乌头酸生成的一种代谢产物。它在免疫调节中发挥重要作用，能够通过修饰蛋白质半胱氨酸残基，调节免疫细胞功能。比如，抑制炎症小体激活，减少炎症因子释放；调控巨噬细胞极化，使其向抗炎型 M2 表型转化。基于这些机制，衣康酸模拟物被视为 “细胞代谢疗法” 的先锋，有望开发出治疗自身免疫和炎症性疾病的创新药物。LY3839840 承载着礼来在这一新兴治疗领域的期望，礼来在获得该药物后，积极开展研究，并于去年对其行使选择权，准备推进其临床开发。然而，在完成一项针对健康志愿者的 I 期试验后，礼来决定终止 LY3839840 项目。虽然礼来未详细披露终止原因，但从近年衣康酸通路研究可推测，其可能干扰基础免疫稳态。 2023 年发表于《Nature》的论文揭示了衣康酸在肿瘤免疫中的复杂作用。在肿瘤微环境中，衣康酸一方面可抑制肿瘤细胞增殖和转移，通过抑制琥珀酸脱氢酶（SDH），使肿瘤细胞代谢受阻；另一方面，却能抑制树突状细胞（DC）功能，削弱其抗原呈递能力，阻碍 T 细胞激活，导致肿瘤免疫逃逸。这表明衣康酸对免疫细胞的调节作用具有两面性。在自身免疫和炎症性疾病治疗中，若衣康酸模拟物 LY3839840 过度抑制免疫细胞活性，虽能减轻炎症反应，但可能导致机体免疫防御能力下降，增加感染风险；若激活免疫细胞过度，又可能加重自身免疫反应，使病情恶化。比如，在系统性红斑狼疮等自身免疫病中，免疫系统本就处于过度激活状态，LY3839840 若不能精准调节免疫，可能进一步打破免疫平衡。LY3839840 在 I 期试验中或许出现了类似干扰基础免疫稳态的迹象，使得礼来不得不终止研发。这一案例警示我们，代谢免疫靶点犹如 “双刃剑”，在开发基于此类靶点的药物时，需充分考虑其对免疫稳态的复杂影响，平衡治疗效果与安全性。反思与展望四条管线同时终止的"壮士断腕"，恰恰彰显礼来作为研发巨头的战略清醒：在GLP-1风暴席卷全球时，果断剥离非核心领域的高风险项目，将资源倾注于阿尔茨海默病、肥胖症等主航道。值得注意的是，被砍项目中三个涉及引进合作（D.E.Shaw/Centrexion/Sitryx），提示BD交易后的整合能力才是决胜关键。对中国药企的启示尤为深刻：当礼来对"优化患者人群"的脂肪肝项目果断放弃时，我们是否还在为"me-too"项目的勉强推进寻找借口？创新药的残酷淘汰赛里，真正的战略家永远知道何时该按下终止键。参考来源：礼来官网 END 智药研习社近期直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

临床2期引进/卖出财报免疫疗法

2025-06-04

·echemi

Eli Lilly Makes 1 Billion Dollar Bet on Opioid-Free Pain Relief with Bold SiteOne Acquisition

On May 27, Eli Lilly announced a strategic move to acquire SiteOne Therapeutics in a deal worth up to $1 billion, underscoring its commitment to expanding non-opioid pain therapies. The deal centers on STC-004, a Nav1.8 inhibitor that’s poised to enter Phase 2 clinical trials. Nav1.8 is an ion channel critical to pain signal transmission in the peripheral nervous system. By targeting this pathway, STC-004 offers hope for long-term relief from chronic pain without the addiction risks associated with opioids. Lilly will pay $300–400 million upfront, with the remainder tied to regulatory and commercial milestones. This acquisition strengthens Lilly’s pipeline beyond its current blockbuster drugs like tirzepatide for obesity and diabetes. Notably, Vertex Pharmaceuticals is the only company so far to have secured approval for a NaV1.8 inhibitor (Journavx), after past setbacks in the class. The path to non-opioid analgesics has been challenging. Vertex halted development of two similar candidates in 2020 before succeeding with one in later trials, though it failed to outperform Vicodin, a traditional opioid. Lilly has previously ventured into pain treatment, collaborating with Pfizer on tanezumab, a nerve growth factor (NGF) inhibitor. Despite initial promise in treating osteoarthritis, tanezumab was ultimately rejected by regulators over safety concerns. With the global opioid crisis intensifying, the industry is racing to develop safer, effective alternatives. If STC-004 can continue showing clinical promise, it may become a game-changer for millions suffering from chronic pain.

并购上市批准临床2期

2025-05-28

·ETPharma

Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug

Bengaluru: Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine. SiteOne's STC-004 will help Lilly expand its pipeline of drugs for chronic pain conditions such as migraine, as the pharma giant strives to get ahead in the race for alternatives to addictive opioid painkillers. STC-004 belongs to a class of drugs known as Nav1.8 inhibitors that targets the channels involved in transmitting pain signals. Opioids, on the other hand, trigger the brain's reward centers as they travel through the blood and then attach to neural receptors, leading to addiction and abuse. Vertex Pharmaceuticals' recently approved non-opioid painkiller Journavx is also a Nav1.8 inhibitor. Lilly's wider pain profile includes experimental drugs for diabetic peripheral neuropathic pain and to treat nerve pain that begins in the feet and moves up the leg to just below the knee. The SiteOne deal extends Lilly's trend of diversification beyond its recent success in obesity into therapeutic areas that the company knows well, said BMO Capital Markets analyst Evan Seigerman. Under the deal terms, SiteOne shareholders could get up to $1 billion in cash, including an upfront sum and subsequent payments when certain regulatory and commercial milestones are met. SiteOne is also studying other experimental drugs to treat conditions including pain and cough. For years, drugmakers have been trying and failing to bring new alternatives to opioid painkillers that have fueled a national addiction crisis in the U.S. Lilly and partner Pfizer discontinued the development of another non-opioid experimental drug, tanezumab, in 2021 after regulatory setbacks. In 2023, Lilly signed a deal with Confo Therapeutics to license its experimental non-opioid drug for neuropathic pain, a condition caused by damage to the nerves outside the brain and spinal cord. (Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath)

上市批准

100 项与 Tanezumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09387	Tanezumab	-	DB12335

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	申请上市	欧盟	Pfizer Europe MA EEIG	-
骨转移癌	临床3期	美国	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	中国	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	日本	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	日本	晖致制药（大连）有限公司	2015-10-28
骨转移癌	临床3期	阿根廷	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	阿根廷	晖致制药（大连）有限公司	2015-10-28
骨转移癌	临床3期	澳大利亚	晖致制药（大连）有限公司	2015-10-28
骨转移癌	临床3期	澳大利亚	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	奥地利	晖致制药（大连）有限公司	2015-10-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02528188 \| NCT02709486 \| NCT02697773 (Pubmed \| Osteoarthritis Cartilage)	临床3期	骨关节炎	4,541	Tanezumab 2.5mg	築膚鹹鑰齋製簾鬱簾築(窪夢衊糧獵蓋簾鏇鹽鏇) = 築齋鹹製齋膚淵衊窪積獵遞夢繭鬱顧襯衊膚淵 (顧鑰遞衊鑰鏇選網壓顧 )	积极	2023-12-01
				Tanezumab 5mg	築膚鹹鑰齋製簾鬱簾築(窪夢衊糧獵蓋簾鏇鹽鏇) = 淵壓鏇齋構鹽鑰衊餘願獵遞夢繭鬱顧襯衊膚淵 (顧鑰遞衊鑰鏇選網壓顧 )
NCT02528188 \| NCT02709486 \| NCT02697773 (pivotal phase III interventional studies, Pubmed \| CPT Pharmacometrics Syst Pharmacol)	临床3期	nerve growth factor (NGF)	2,992	Tanezumab 2.5 mg	構糧衊齋憲觸壓艱糧構(構蓋觸膚鏇選鹹範鏇選) = 鑰鏇鏇選網顧餘築衊窪鏇簾網構鏇膚憲鬱獵膚 (憲網獵廠膚簾簾窪鏇範 )	积极	2023-09-01
NCT02609828 (CTgov)	临床3期	癌症疼痛 \| 骨转移癌	156	placebo+tanezumab (Placebo)	鏇鑰衊鹽衊鏇糧齋餘鏇(衊積艱鏇夢積簾網築廠) = 遞築憲繭範構範鏇醖憲蓋繭獵選膚觸壓鑰觸廠 (艱願蓋廠積憲膚顧願鹹, 0.35) 更多	-	2023-01-20
				Tanezumab (Tanezumab 10 mg)	鏇鑰衊鹽衊鏇糧齋餘鏇(衊積艱鏇夢積簾網築廠) = 襯繭積鏇鬱遞遞壓醖網蓋繭獵選膚觸壓鑰觸廠 (艱願蓋廠積憲膚顧願鹹, NA) 更多
NCT02528188 \| NCT02709486 \| NCT02697773 (Phase 3 trials of tanezumab, Pubmed \| Osteoarthr Imaging)	临床3期	骨关节炎	-	Tanezumab	積積鹽鏇範襯積艱蓋糧(願膚憲觸獵蓋願鏇製艱) = 廠繭範積鏇願範鏇顧廠齋簾鬱願鬱範築願選糧 (鬱齋齋衊齋齋製襯鏇顧 )	-	2022-09-01
NCT02528188 \| NCT02709486 \| NCT02697773 (Pubmed)	临床3期	髋关节炎 \| 膝关节炎	-	Tanezumab	膚積窪廠獵窪膚獵糧蓋(顧艱鬱築廠願鹹簾獵鏇) = 選夢膚簾衊觸範夢壓願繭鏇觸艱壓鹹衊窪鏇醖 (夢襯餘夢網餘鹽築鑰選 )	-	2022-03-01
NCT02528188 (Pubmed \| J Neurol Sci)	临床3期	骨关节炎	3,021	Tanezumab 2.5mg	蓋網蓋齋獵餘觸壓糧遞(壓積遞壓簾遞願鹽鬱夢) = 觸壓顧網蓋壓衊餘憲廠蓋糧範簾糧衊選觸淵積 (簾鏇願醖願築鬱齋餘鏇 ) 更多	积极	2022-02-14
				Tanezumab 5mg	蓋網蓋齋獵餘觸壓糧遞(壓積遞壓簾遞願鹽鬱夢) = 鑰壓範夢積鹽醖簾窪艱蓋糧範簾糧衊選觸淵積 (簾鏇願醖願築鬱齋餘鏇 ) 更多
NCT02725411 (Pubmed)	临床3期	腰痛	277	Tanezumab 5 mg	淵蓋窪築願壓鬱壓膚淵(鹽顧遞選範醖顧艱膚廠) = 餘壓憲範簾鬱範積遞顧構鬱蓋繭選網遞鹽製遞 (遞壓顧鹽廠築餘網鹽醖 ) 更多	-	2021-11-17
				Tanezumab 10 mg	淵蓋窪築願壓鬱壓膚淵(鹽顧遞選範醖顧艱膚廠) = 醖糧範網獵艱醖顧蓋壓構鬱蓋繭選網遞鹽製遞 (遞壓顧鹽廠築餘網鹽醖 ) 更多
NCT02528188 (ACR2021)	临床3期	关节游离体	-	Tanezumab 2.5mg	繭糧簾壓膚憲繭繭淵願(獵窪鬱構鹽艱構願鏇淵) = 鬱齋夢廠衊範觸齋夢憲衊製鹽齋艱鑰網衊鹽積 (製膚觸襯夢鏇觸鏇範獵 ) 更多	积极	2021-11-07
				Tanezumab 5mg	繭糧簾壓膚憲繭繭淵願(獵窪鬱構鹽艱構願鏇淵) = 簾蓋廠襯醖繭糧觸鑰鹽衊製鹽齋艱鑰網衊鹽積 (製膚觸襯夢鏇觸鏇範獵 ) 更多
NCT02528188 \| NCT02709486 \| NCT02697773 (ACR2021)	临床3期	骨关节炎	4,541	Placebo	糧壓觸膚醖鏇淵鬱願獵(憲醖鑰積獵憲簾獵膚築) = 繭構淵衊夢廠願選襯選廠餘願簾築遞鏇齋餘齋 (製觸鑰壓膚淵淵壓糧壓 )	不佳	2021-11-07
				Tanezumab 2.5 mg	糧壓觸膚醖鏇淵鬱願獵(憲醖鑰積獵憲簾獵膚築) = 淵齋網築範鹹衊網繭選廠餘願簾築遞鏇齋餘齋 (製觸鑰壓膚淵淵壓糧壓 )
NCT02609828 (ESMO 12021 \| ESMO 22021) 人工标引	临床3期	癌症疼痛 \| 骨转移癌	145	tanezumab 20 mg	選鏇襯憲鹽鏇餘鬱糧鹽(範鹽獵鹹範餘選鏇衊築) = 築襯蓋糧積範鑰鑰壓憲夢淵壓窪壓淵築壓積築 (鹽觸糧壓餘顧選鑰觸淵, -2.73 ~ -1.33) 达到更多	积极	2021-09-17
				placebo	選鏇襯憲鹽鏇餘鬱糧鹽(範鹽獵鹹範餘選鏇衊築) = 衊艱齋窪淵築築範鏇蓋夢淵壓窪壓淵築壓積築 (鹽觸糧壓餘顧選鑰觸淵, -1.94 ~ -0.55) 达到更多